Antitumour Immune Response and Cancer Vaccination: The Critical Role of Dendritic Cells

References

• Van Pel A., Van der Bruggen P., Coulie P. G. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 1995; 145: 229–2501. Van Pel A., Van der Bruggen P., Coulie P. G. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 1995; 145: 229–250
   PubMed Web of Science ®Google Scholar
• Boon T., Van der Bruggen P. Human tumor antigens recognized by T. lymphocytes. J. Exp. Med. 1996; 183: 725–7292. Boon T., Van der Bruggen P. Human tumor antigens recognized by T. lymphocytes. J. Exp. Med. 1996; 183: 725–729
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C., Bertazolli C., Dermine S. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancer. Clin. Cancer Res. 1997; 3: 6753. Gambacorti-Passerini C., Bertazolli C., Dermine S. Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancer. Clin. Cancer Res. 1997; 3: 675
   PubMed Web of Science ®Google Scholar
• Bakker A. B. H., Marland G., De Boer A. J. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells. in vitro. Cancer Res. 1995; 55: 5330–53344. Bakker A. B. H., Marland G., De Boer A. J. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells. in vitro. Cancer Res. 1995; 55: 5330–5334
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 1997; 11: 129–1635. Matzinger P. Tolerance, danger, and the extended family. Ann. Rev. Immunol. 1997; 11: 129–163
   Google Scholar
• Austyn J. M. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 1996; 183: 1287–12926. Austyn J. M. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 1996; 183: 1287–1292
   PubMed Web of Science ®Google Scholar
• Linsley P. S., Brady W., Grosmaire L. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991; 173: 721–7307. Linsley P. S., Brady W., Grosmaire L. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991; 173: 721–730
   PubMed Web of Science ®Google Scholar
• Lanzaracchia A. Licence to kill. Nature 1998; 393: 413–4148. Lanzaracchia A. Licence to kill. Nature 1998; 393: 413–414
   PubMed Web of Science ®Google Scholar
• Nair S., Babtt J. S., Dunham R. G. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 1993; 67: 4062–40699. Nair S., Babtt J. S., Dunham R. G. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 1993; 67: 4062–4069
   PubMed Web of Science ®Google Scholar
• Mackay C. R. Homing of naive, memory and effector lymphocytes. Curr Opin. Immunol. 1993; 5: 423–42710. Mackay C. R. Homing of naive, memory and effector lymphocytes. Curr Opin. Immunol. 1993; 5: 423–427
   PubMed Web of Science ®Google Scholar
• Ridge J. P., Fuchs J. E., Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996; 271: 1723–172611. Ridge J. P., Fuchs J. E., Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996; 271: 1723–1726
   PubMed Web of Science ®Google Scholar
• Speiser D. E., Miranda R., Zaharian A. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997; 186: 645–65312. Speiser D. E., Miranda R., Zaharian A. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997; 186: 645–653
   PubMed Web of Science ®Google Scholar
• Coulie P. G., Lehmann F., Lethe B. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 1995; 92: 7976–798013. Coulie P. G., Lehmann F., Lethe B. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 1995; 92: 7976–7980
   PubMed Web of Science ®Google Scholar
• Cohen E. P., Kim T. S. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 1994; 5: 419–42814. Cohen E. P., Kim T. S. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 1994; 5: 419–428
   Google Scholar
• Cromme F. V., Airey J., Heemels M. T. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 1994; 179: 335–34015. Cromme F. V., Airey J., Heemels M. T. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 1994; 179: 335–340
   PubMed Web of Science ®Google Scholar
• Chang H. L., Gillett N., Figari I. Increased transforming growth factor beta expression inhibits cell proliferation in vitro yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 1993; 53: 4391–439616. Chang H. L., Gillett N., Figari I. Increased transforming growth factor beta expression inhibits cell proliferation in vitro yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 1993; 53: 4391–4396
   PubMed Web of Science ®Google Scholar
• Chen Q., Daniel V., Maher D. W. Production of IL-10 by melanoma cells: examination of its role in immunosuppression. Int. J. Cancer 1994; 56: 755–75917. Chen Q., Daniel V., Maher D. W. Production of IL-10 by melanoma cells: examination of its role in immunosuppression. Int. J. Cancer 1994; 56: 755–759
   PubMed Web of Science ®Google Scholar
• Inaba K., Pack M., Inaba M. High levels of major histocompatibility complex II-self peptides on dendritic cells from the T cell arcas of lymph nodes. J. Exp. Med. 1997; 186: 665–67218. Inaba K., Pack M., Inaba M. High levels of major histocompatibility complex II-self peptides on dendritic cells from the T cell arcas of lymph nodes. J. Exp. Med. 1997; 186: 665–672
   PubMed Web of Science ®Google Scholar
• Steinman R. M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 1991; 9: 271–29619. Steinman R. M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 1991; 9: 271–296
   PubMed Web of Science ®Google Scholar
• Banchereau J., Steinman R. M. Dendritic cells and the control of immunity (review of 103 refs). Nature 1998; 392: 245–25220. Banchereau J., Steinman R. M. Dendritic cells and the control of immunity (review of 103 refs). Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Romani N., Gruner S., Brang D. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 1994; 180: 83–9321. Romani N., Gruner S., Brang D. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 1994; 180: 83–93
   PubMed Web of Science ®Google Scholar
• Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 1994; 179: 1109–111822. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 1994; 179: 1109–1118
   PubMed Web of Science ®Google Scholar
• Romani R., Reider D., Heuer M. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 1996; 196: 137–15123. Romani R., Reider D., Heuer M. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 1996; 196: 137–151
   PubMed Web of Science ®Google Scholar
• Zitvogel L., Mayordomo J. I., Tjandrawan T. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996; 183: 87–9724. Zitvogel L., Mayordomo J. I., Tjandrawan T. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996; 183: 87–97
   PubMed Web of Science ®Google Scholar
• Bernard J., Ittelet D., Christoph A. Adherent-free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use. Hematol. Cell. Ther. 1998; 40: 17–2625. Bernard J., Ittelet D., Christoph A. Adherent-free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use. Hematol. Cell. Ther. 1998; 40: 17–26
   PubMedGoogle Scholar
• Eymard J. C., Lopez M., Cattan A. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur. J. Cancer 1996; 32A: 1905–191126. Eymard J. C., Lopez M., Cattan A. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur. J. Cancer 1996; 32A: 1905–1911
   PubMed Web of Science ®Google Scholar
• Morse M. A., Lyerly H. K. Immunotherapy of cancer using dendritic cells. Cyt. Cell. Mol. Ther. 1998; 4: 35–4427. Morse M. A., Lyerly H. K. Immunotherapy of cancer using dendritic cells. Cyt. Cell. Mol. Ther. 1998; 4: 35–44
   PubMedGoogle Scholar
• Hsu F. J., Benike C., Fagnoni P. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 1996; 2: 5228. Hsu F. J., Benike C., Fagnoni P. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 1996; 2: 52
   PubMed Web of Science ®Google Scholar
• Salgaller M. L., Lodge P. A., McLean J. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). The Prostate 1998; 35: 144–15129. Salgaller M. L., Lodge P. A., McLean J. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). The Prostate 1998; 35: 144–151
   PubMed Web of Science ®Google Scholar
• Nestle F. O., Alijagic S., Gilliet M. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 1998; 4: 328–33230. Nestle F. O., Alijagic S., Gilliet M. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 1998; 4: 328–332
   PubMed Web of Science ®Google Scholar